Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder

Lode J. Swinnen, Michael Leblanc, Thomas M. Grogan, Leo I. Gordon, Patrick J. Stiff, Alan M. Miller, Yvette Kasamon, Thomas P Miller, Richard I. Fisher

Research output: Contribution to journalArticle

70 Citations (Scopus)

Abstract

BACKGROUND.: Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. METHODS.: Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for 1 week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. RESULTS.: Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR. Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection. Only 1 of 13 (7%) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years. CONCLUSIONS.: Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to RI as initial therapy. Chemotherapy resulted in 57% durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab.

Original languageEnglish (US)
Pages (from-to)215-222
Number of pages8
JournalTransplantation
Volume86
Issue number2
DOIs
StatePublished - Jul 27 2008

Fingerprint

interferon alfa-2b
Lymphoproliferative Disorders
Immunosuppressive Agents
Immunosuppression
Prospective Studies
Drug Therapy
Interferons
Acyclovir
Tacrolimus

Keywords

  • Immunosuppressive reduction
  • Lymphoma
  • PTLD
  • S9239

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Cite this

Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. / Swinnen, Lode J.; Leblanc, Michael; Grogan, Thomas M.; Gordon, Leo I.; Stiff, Patrick J.; Miller, Alan M.; Kasamon, Yvette; Miller, Thomas P; Fisher, Richard I.

In: Transplantation, Vol. 86, No. 2, 27.07.2008, p. 215-222.

Research output: Contribution to journalArticle

Swinnen, Lode J. ; Leblanc, Michael ; Grogan, Thomas M. ; Gordon, Leo I. ; Stiff, Patrick J. ; Miller, Alan M. ; Kasamon, Yvette ; Miller, Thomas P ; Fisher, Richard I. / Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder. In: Transplantation. 2008 ; Vol. 86, No. 2. pp. 215-222.
@article{27b2648ff39247ccadbf20f9216d8201,
title = "Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder",
abstract = "BACKGROUND.: Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. METHODS.: Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50{\%} for 2 weeks; a further 50{\%} reduction for 1 week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. RESULTS.: Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5{\%}), no CR. Progressive disease occurred in 8 of 16 (50{\%}) and 6 of 16 (38{\%}) experienced rejection. Only 1 of 13 (7{\%}) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67{\%}) achieving CR, four of five durable beyond 2 years. CONCLUSIONS.: Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to RI as initial therapy. Chemotherapy resulted in 57{\%} durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab.",
keywords = "Immunosuppressive reduction, Lymphoma, PTLD, S9239",
author = "Swinnen, {Lode J.} and Michael Leblanc and Grogan, {Thomas M.} and Gordon, {Leo I.} and Stiff, {Patrick J.} and Miller, {Alan M.} and Yvette Kasamon and Miller, {Thomas P} and Fisher, {Richard I.}",
year = "2008",
month = "7",
day = "27",
doi = "10.1097/TP.0b013e3181761659",
language = "English (US)",
volume = "86",
pages = "215--222",
journal = "Transplantation",
issn = "0041-1337",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Prospective study of sequential reduction in immunosuppression, interferon alpha-2B, and chemotherapy for posttransplantation lymphoproliferative disorder

AU - Swinnen, Lode J.

AU - Leblanc, Michael

AU - Grogan, Thomas M.

AU - Gordon, Leo I.

AU - Stiff, Patrick J.

AU - Miller, Alan M.

AU - Kasamon, Yvette

AU - Miller, Thomas P

AU - Fisher, Richard I.

PY - 2008/7/27

Y1 - 2008/7/27

N2 - BACKGROUND.: Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. METHODS.: Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for 1 week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. RESULTS.: Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR. Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection. Only 1 of 13 (7%) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years. CONCLUSIONS.: Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to RI as initial therapy. Chemotherapy resulted in 57% durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab.

AB - BACKGROUND.: Several interventions can cure posttransplant lymphoproliferative disease (PTLD); a sequential approach is usual, starting with reduction in immunosuppressives (RI). The efficacy of RI remains poorly defined, particularly in adults. We assessed an algorithm starting with a defined course of RI in all patients, escalating to interferon (IFN) alpha2b, and finally to chemotherapy, in a prospective multicenter phase II study of adult solid organ transplant recipients. The design predated rituximab. METHODS.: Reduction in immunosuppressives: cyclosporine or tacrolimus reduction by 50% for 2 weeks; a further 50% reduction for 1 week if not in complete remission (CR). Intravenous acyclovir was given for the duration of all RI. Patients with less than CR, or any rejection, resumed immunosuppressives and proceeded to IFN 3 MIU/m/day for up to 3 months; if less than CR, ProMACE-CytaBOM chemotherapy. RESULTS.: Twenty patients were registered over 60 months; 16 patients with biopsy-proven PTLD were eligible (13 heart, 3 kidney recipients). Median age was 47 (24-75) years. Reduction in immunosuppressives resulted in only 1 of 16 partial responses (12.5%), no CR. Progressive disease occurred in 8 of 16 (50%) and 6 of 16 (38%) experienced rejection. Only 1 of 13 (7%) patients achieved durable CR with IFN. Seven eligible patients received ProMACE-CytaBOM chemotherapy, five of seven (67%) achieving CR, four of five durable beyond 2 years. CONCLUSIONS.: Reduction in immunosuppressives produced no CR, progressive disease and rejection were frequent; response to IFN was rare. A strong case can be made for adding rituximab to RI as initial therapy. Chemotherapy resulted in 57% durable CR, data that are relevant for the up to two thirds of PTLD patients who are refractory to rituximab.

KW - Immunosuppressive reduction

KW - Lymphoma

KW - PTLD

KW - S9239

UR - http://www.scopus.com/inward/record.url?scp=49249097559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49249097559&partnerID=8YFLogxK

U2 - 10.1097/TP.0b013e3181761659

DO - 10.1097/TP.0b013e3181761659

M3 - Article

C2 - 18645482

AN - SCOPUS:49249097559

VL - 86

SP - 215

EP - 222

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 2

ER -